# A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

> **NCT06281236** · PHASE1 · TERMINATED · sponsor: **Sparrow Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Polymyalgia Rheumatica

## Interventions

- **DRUG:** Prednisolone
- **DRUG:** SPI-62

## Key facts

- **NCT ID:** NCT06281236
- **Lead sponsor:** Sparrow Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-22
- **Primary completion:** 2025-03-25
- **Final completion:** 2025-04-25
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** lack of enrollment
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06281236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06281236, "A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06281236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*